New pharmacotherapy options for pulmonary arterial hypertension

Bibliography

• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-41
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36
   PubMed Web of Science ®Google Scholar
• Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63
   PubMed Web of Science ®Google Scholar
• Chaumais M-C, Macari EA, Sitbon O. Calcium-channel blockers in pulmonary arterial hypertension. Handb Exp Pharmacol 2013;218:161-75
   PubMedGoogle Scholar
• Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11
   PubMed Web of Science ®Google Scholar
• Jing Z-C, Jiang X, Han Z-Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;33:1354-60
   PubMed Web of Science ®Google Scholar
• Barst RJ, Gibbs JSR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S78-84
   PubMed Web of Science ®Google Scholar
• Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81
   PubMed Web of Science ®Google Scholar
• Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:890-6
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485-91
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301
   PubMed Web of Science ®Google Scholar
• Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62:D60-72
   PubMed Web of Science ®Google Scholar
• Kallen AJ, Lederman E, Balaji A, et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 2008;29:342-9
   PubMed Web of Science ®Google Scholar
• Chaumais M-C, Jobard M, Huertas A, et al. Pharmacokinetic evaluation of continuous intravenous epoprostenol. Expert Opin Drug Metab Toxicol 2010;6:1587-98
   PubMed Web of Science ®Google Scholar
• Magnani B, Galiè N. Prostacyclin in primary pulmonary hypertension. Eur Heart J 1996;17:18-24
   PubMed Web of Science ®Google Scholar
• Ahearn GS, Selim MA, Tapson VF. Severe erythroderma as a complication of continuous epoprostenol therapy. Chest 2002;122:378-80
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8
   PubMed Web of Science ®Google Scholar
• Chin KM, Channick RN, de Lemos JA, et al. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest 2009;135:130-6
   PubMed Web of Science ®Google Scholar
• Szczeklik A, Pietoń R, Sieradzki J, Nizankowski R. The effects of prostacyclin on glycemia and insulin release in man. Prostaglandins 1980;19:959-68
   PubMed Web of Science ®Google Scholar
• Hackman AM, Lackner TE. Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years. Pharmacother J Hum Pharmacol Drug Ther 2006;26:68-94
   Web of Science ®Google Scholar
• Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014;43:1691-7
   PubMed Web of Science ®Google Scholar
• Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010;104:9-21
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4
   PubMed Web of Science ®Google Scholar
• Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-203
   PubMed Web of Science ®Google Scholar
• Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-43
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31:891-901
   PubMed Web of Science ®Google Scholar
• Sadushi-Koliçi R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant Off Publ Int Soc Heart Transplant 2012;31:735-43
   PubMed Web of Science ®Google Scholar
• Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004;44:209-14
   PubMed Web of Science ®Google Scholar
• Sitbon O, Manes A, Jais X, et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 2007;49:1-5
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;172:1586-9
   PubMed Web of Science ®Google Scholar
• Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant Off Publ Int Soc Heart Transplant 2010;29:137-49
   PubMed Web of Science ®Google Scholar
• Farber HW, Walkey AJ, O’Donnell MR. Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension. J Heart Lung Transplant Off Publ Int Soc Heart Transplant 2010;29:825-6
   PubMed Web of Science ®Google Scholar
• Minai OA, Parambil J, Dweik RA, et al. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. Respir Med 2013;107:458-65
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-22
   PubMed Web of Science ®Google Scholar
• Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study):a randomized controlled trial. Chest 2012;142:1383-90
   PubMed Web of Science ®Google Scholar
• Tapson VF, Jing Z-C, Xu K-F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study):a randomized controlled trial. Chest 2013;144:952-8
   PubMed Web of Science ®Google Scholar
• Jing Z-C, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013;127:624-33
   PubMed Web of Science ®Google Scholar
• Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986;30:61-8
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63
   PubMed Web of Science ®Google Scholar
• Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005;26:1895-902
   PubMed Web of Science ®Google Scholar
• Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003;24:356-65
   PubMed Web of Science ®Google Scholar
• Higenbottam TW, Butt AY, Dinh-Xaun AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart Br Card Soc 1998;79:175-9
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009;34:132-7
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiéry J-L, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25
   PubMed Web of Science ®Google Scholar
• Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol 1995;35:235-55
   PubMed Web of Science ®Google Scholar
• Seo B, Oemar BS, Siebenmann R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994;89:1203-8
   PubMed Web of Science ®Google Scholar
• Eguchi S, Hirata Y, Imai T, Marumo F. Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculature. Endocrinology 1993;132:524-9
   PubMed Web of Science ®Google Scholar
• Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35
   PubMed Web of Science ®Google Scholar
• Kim NHS, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther 2002;7:9-19
   PubMedGoogle Scholar
• Dupuis J, Cernacek P, Tardif JC, et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 1998;135:614-20
   PubMed Web of Science ®Google Scholar
• Frasch HF, Marshall C, Marshall BE. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol 1999;276:L304-10
   PubMed Web of Science ®Google Scholar
• Cacoub P, Dorent R, Nataf P, et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 1997;33:196-200
   PubMed Web of Science ®Google Scholar
• Venitz J, Zack J, Gillies H, et al. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol 2012;52:1784-805
   PubMed Web of Science ®Google Scholar
• Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):a double-blind, randomised controlled trial. Lancet 2008;371:2093-100
   PubMed Web of Science ®Google Scholar
• Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23
   PubMed Web of Science ®Google Scholar
• Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9
   PubMed Web of Science ®Google Scholar
• Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27:589-95
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galiè N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol 2014;172:332-9
   PubMed Web of Science ®Google Scholar
• Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-31
   PubMed Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J Off J Eur Soc Clin Respir Physiol 2007;30:338-44
   PubMed Web of Science ®Google Scholar
• Dhillon S, Keating GM. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am J Cardiovasc Drugs Drugs Devices Interv 2009;9:331-50
   PubMed Web of Science ®Google Scholar
• Wilkins MR. Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:433-4
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Keam SJ. Ambrisentan. Drugs 2008;68:2195-204
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Dufton C, Gerber MJ. Ambrisentan for pulmonary arterial hypertension. Future Cardiol 2005;1:425-32
   PubMedGoogle Scholar
• Hoeper MM. Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs 2005;65:1337-54
   PubMed Web of Science ®Google Scholar
• Casserly B, Klinger JR. Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des Devel Ther 2009;2:265-80
   PubMedGoogle Scholar
• Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35
   PubMed Web of Science ®Google Scholar
• Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-19
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:1971-81
   PubMed Web of Science ®Google Scholar
• Blalock SE, Matulevicius S, Mitchell LC, et al. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail 2010;16:121-7
   PubMed Web of Science ®Google Scholar
• Trow TK, Taichman DB. Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism. Respir Med 2009;103:951-62
   PubMed Web of Science ®Google Scholar
• Schirger JA, Chen HH, Jougasaki M, et al. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation 2004;109:249-54
   PubMed Web of Science ®Google Scholar
• Montani D, Chaumais M-C, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 2014;141(2):172-91
   PubMed Web of Science ®Google Scholar
• McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-9
   PubMed Web of Science ®Google Scholar
• Frampton JE. Ambrisentan. Am J Cardiovasc Drugs Drugs Devices Interv 2011;11:215-26
   PubMed Web of Science ®Google Scholar
• Spence R, Mandagere A, Richards DB, et al. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther 2010;88:513-20
   PubMed Web of Science ®Google Scholar
• Ciracì R, Tirone G, Scaglione F. The impact of drug-drug interactions on pulmonary arterial hypertension therapy. Pulm Pharmacol Ther 2014;28(1):1-8
   PubMed Web of Science ®Google Scholar
• Kingman M, Ruggiero R, Torres F. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2009;10:1847-58
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Olsson KM, Schneider A, Golpon H. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur Respir J 2009;33:1518-19
   PubMed Web of Science ®Google Scholar
• Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009;34:770-1
   PubMed Web of Science ®Google Scholar
• Lee W-TN, Kirkham N, Johnson MK, et al. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension. Eur Respir J 2011;37:472-4
   PubMed Web of Science ®Google Scholar
• Steinhorn RH. Nitric oxide and beyond: new insights and therapies for pulmonary hypertension. J Perinatol Off J Calif Perinat Assoc 2008;28(Suppl 3):S67-71
   PubMed Web of Science ®Google Scholar
• Zuckerbraun BS, George P, Gladwin MT. Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. Cardiovasc Res 2011;89:542-52
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study. J Am Coll Cardiol 2004;44:1488-96
   PubMed Web of Science ®Google Scholar
• Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006;60:967-75
   PubMed Web of Science ®Google Scholar
• Montani D, Chaumais M-C, Savale L, et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009;26:813-25
   PubMed Web of Science ®Google Scholar
• Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64:43-50
   PubMed Web of Science ®Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
   PubMed Web of Science ®Google Scholar
• Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149-53
   PubMed Web of Science ®Google Scholar
• Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010;31:1124-31
   PubMed Web of Science ®Google Scholar
• Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006;151:851.e1-5
   PubMed Web of Science ®Google Scholar
• Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011;140:1274-83
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J Off J Eur Soc Clin Respir Physiol 2004;24:1007-10
   PubMed Web of Science ®Google Scholar
• Vachiery J-L, Huez S, Gillies H, et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol 2011;71:289-92
   PubMed Web of Science ®Google Scholar
• Revatio, INN: sildenafil - WC500107804.pdf [Internet]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000638/WC500107804.pdf [Last accessed 18 March 2013]
   Google Scholar
• Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012;125:324-34
   PubMed Web of Science ®Google Scholar
• Drug Safety and Availability > FDA Drug Safety Communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension [Internet]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm [Last accessed 13 January 2013]
   Google Scholar
• Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Brundage BH, Galiè N, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 2012;60:768-74
   PubMed Web of Science ®Google Scholar
• Jing Z-C, Jiang X, Wu B-X, et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart Br Card Soc 2009;95:1531-6
   PubMed Web of Science ®Google Scholar
• Jing Z-C, Yu Z-X, Shen J-Y, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011;183:1723-9
   PubMed Web of Science ®Google Scholar
• Wirostko BM, Tressler C, Hwang L-J, et al. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. BMJ 2012;344:e554
   PubMed Web of Science ®Google Scholar
• Lambert O, Bandilla D, Iyer R, et al. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted. Drug Des Devel Ther 2012;6:61-70
   PubMed Web of Science ®Google Scholar
• Fuentes A, Coralic A, Dawson KL. A new epoprostenol formulation for the treatment of pulmonary arterial hypertension. Am J Health-Syst Pharm 2012;69:1389-93
   PubMed Web of Science ®Google Scholar
• Sitbon O, Delcroix M, Bergot E, et al. EPITOME-2:An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J 2014;167:210-17
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007;322:1181-8
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008;326:691-9
   PubMed Web of Science ®Google Scholar
• Morrison K, Studer R, Ernst R, et al. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery. J Pharmacol Exp Ther 2012;343:547-55
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012;40:874-80
   PubMed Web of Science ®Google Scholar
• Forrest AS, Hennig GW, Jokela-Willis S, et al. Prostaglandin regulation of gastric slow waves and peristalsis. Am J Physiol Gastrointest Liver Physiol 2009;296:G1180-90
   PubMed Web of Science ®Google Scholar
• Kan KKW, Jones RL, Ngan M-P, Rudd JA. Actions of prostanoids to induce emesis and defecation in the ferret. Eur J Pharmacol 2002;453:299-308
   PubMed Web of Science ®Google Scholar
• Morrison K, Ernst R, Hess P, et al. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther 2010;335:249-55
   PubMed Web of Science ®Google Scholar
• Pal A, Brasseur JG, Abrahamsson B. A stomach road or “Magenstrasse” for gastric emptying. J Biomech 2007;40:1202-10
   PubMed Web of Science ®Google Scholar
• Minami T, Nakano H, Kobayashi T, et al. Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br J Pharmacol 2001;133:438-44
   PubMed Web of Science ®Google Scholar
• Southall MD, Vasko MR. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. J Biol Chem 2001.276:16083-91
   Google Scholar
• Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension [Internet]. Available from: http://www1.actelion.com/en/journalists/news-archive.page?newsId=1793163 [Last accessed 21 June 2015]
   Google Scholar
• Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 2012;7:e47662
   PubMed Web of Science ®Google Scholar
• Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 2012;55:7849-61
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Sidharta PN, Maddrey WC, et al. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf 2014;13(3):391-405
   PubMed Web of Science ®Google Scholar
• Sidharta PN, van Giersbergen PLM, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011;67:977-84
   PubMed Web of Science ®Google Scholar
• Bruderer S, Hopfgartner G, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica Fate Foreign Compd Biol Syst 2012;42:901-10
   PubMed Web of Science ®Google Scholar
• Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809-18
   PubMed Web of Science ®Google Scholar
• Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013;42:1622-32
   PubMed Web of Science ®Google Scholar
• Weiss J, Theile D, Rüppell MA, et al. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol 2013;701:168-75
   PubMed Web of Science ®Google Scholar
• Bruderer S, Marjason J, Sidharta PN, Dingemanse J. Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex. Pharmacology 2013;91:331-8
   PubMed Web of Science ®Google Scholar
• Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet 2013;52:685-92
   PubMed Web of Science ®Google Scholar
• Bruderer S, Aänismaa P, Homery M-C, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J 2012;14:68-78
   PubMed Web of Science ®Google Scholar
• Sidharta PN, Lindegger N, Ulč I, Dingemanse J. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. J Clin Pharmacol 2014;54(3):291-300
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Stasch J-P, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32:881-91
   PubMed Web of Science ®Google Scholar
• Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003;93:96-105
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 2011;20:567-76
   PubMed Web of Science ®Google Scholar
• Lang M, Kojonazarov B, Tian X, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One 2012;7:e43433
   PubMed Web of Science ®Google Scholar
• Frey R, Mück W, Unger S, et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521:an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008;48:926-34
   PubMed Web of Science ®Google Scholar
• Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J Off J Eur Soc Clin Respir Physiol 2009;33:785-92
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J Off J Eur Soc Clin Respir Physiol 2010;36:792-9
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319-29
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127:1128-38
   PubMed Web of Science ®Google Scholar
• Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128-37
   PubMed Web of Science ®Google Scholar
• Odagiri K, Watanabe H. Effects of the rho-kinase inhibitor, fasudil, on pulmonary hypertension. Circ J Off J Jpn Circ Soc 2015;79:1213-14
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Yamada N, Matsubara H, et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J 2013;77:2619-25
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Guignabert C, Barlier-Mur A-M, et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006;113:1857-64
   PubMed Web of Science ®Google Scholar
• Price LC, Montani D, Tcherakian C, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 2011;37:813-22
   PubMed Web of Science ®Google Scholar
• Chaumais M-C, Ranchoux B, Montani D, et al. N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respir Res 2014;15:65
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008;32:1289-94
   PubMed Web of Science ®Google Scholar
• Wang X-X, Zhang F-R, Shang Y-P, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007;49:1566-71
   PubMed Web of Science ®Google Scholar
• Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014;129:57-65
   PubMed Web of Science ®Google Scholar
• GSK announces first-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study | GSK [Internet]. Available from: http://www.gsk.com:33011/en-gb/media/press-releases/2014/gsk-announces-first-line-combination-of-ambrisentan-and-tadalafil-reduces-risk-of-clinical-failure-compared-to-monotherapy-in-pulmonary-arterial-hypertension-outcomes-study/ [Last accessed 21 June 2015]
   Google Scholar